OXBOF Stock Chart & Stats
$0.01
<$0.01(25.00%)
At close: 4:00 PM EDT
$0.01
<$0.01(25.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.06
Previous CloseN/A
Volume264.84K
Average Volume (3M)3.00
Market Cap
$6.85M
Enterprise Value$7.45M
Total Cash (Recent Filing)$2.51M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit-2.25
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$23.83K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive revenue growth indicates increasing commercial activity and demand for Oxford BioDynamics’ offerings. If sustained, it can improve operating leverage and support broader adoption of its diagnostic tests and platform partnerships.
Proprietary EpiSwitch PlatformThe EpiSwitch platform provides a differentiated technology base in molecular diagnostics and precision medicine. Proprietary biomarker capabilities may support new tests, licensing opportunities and partnerships across clinical and life-science markets.
Diversified Commercialization ModelMultiple monetization routes reduce reliance on a single product or customer type. Test sales can provide operating revenue, while licensing and collaborations may create milestone, royalty or partner-funded opportunities.
Bears Say
Persistent UnprofitabilityOngoing losses and negative operating margins show that revenue has not yet translated into sustainable profitability. Continued cost pressure could limit reinvestment capacity and increase dependence on external financing.
High Financial LeverageHeavy reliance on debt reduces financial flexibility and increases exposure to refinancing and repayment demands. Low equity backing and negative returns raise the risk that future funding could dilute shareholders or constrain growth.
Weak Cash Flow TrendDeclining free cash flow and weak operating cash conversion indicate that the business is not yet generating dependable internal funding. This may require additional capital to sustain development, commercialization and operating commitments.
Oxford BioDynamics News
OXBOF FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is $6.85M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 151 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 30, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in OXBOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―